Tag
Secondary analysis of TEMPO-2 trial data reveals intracranial hemorrhage in minor stroke patients increases 90-day mortality risk threefold, with higher hemorrhage rates in tenecteplase-treated patients despite most bleeds being non-symptom
A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in
A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hou
A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved func
This longitudinal study reveals persistent cognitive, physical, and vascular challenges up to 9 years after minor lacunar or cortical ischemic stroke, emphasizing different risks and recovery patterns by stroke subtype.
